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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: Juvenile dermatomyositis is a rare childhood multisystem autoimmune disease
involving primarily the skin and muscles, and it may lead to long-term disability. This study
aimed to describe the clinical course of juvenile dermatomyositis and determine if any early
clinical or laboratory features could predict outcome.
Methods: Medical charts of patients aged 18 years and diagnosed with juvenile dermatomy-
ositis (according to the criteria of Bohan and Peter) at the Pediatric Department, National
Taiwan University Hospital, between 1989 and 2009 were reviewed. The endpoints for disease
assessment were complete clinical response and complete clinical remission. Cox’s propor-
tional hazards model was fitted to identify important predictors of complete clinical remis-
sion.
Results: A total of 39 patients with juvenile dermatomyositis were reviewed. Two-thirds were
females, and the mean age at disease onset was 81.97  46.63 months. The most common
initial presentations were Gottron’s papule (82.1%) and muscle weakness (82.1%). After
excluding one patient with an incomplete record, the remaining 31 patients who had muscle
weakness were analyzed; among them, 22 (70.97%) achieved complete clinical response, but
only six (19.4%) achieved complete clinical remission. Multivariate analysis showed that fe-
male sex, negative Gowers’ sign at disease onset, and positive photosensitivity at disease
onset were favorable factors to achieve complete clinical remission. Moreover, covariate-
adjusted survival curves were drawn for making predictions of complete clinical remission.
Only 13 (33.33%) patients were symptom free at the end of follow up, whereas the other 26
suffered from different kinds of complications. None of them developed malignancy, but
two (5.13%) patients died during the follow-up period.of Pediatrics, National Taiwan University Hospital, Room 17038, 17F, Children’s Hospital Building,
1, Taiwan.
tw (B.-L. Chiang).
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32 C. Sun et alConclusion: Factors such as male sex and Gowers’ sign were unlikely to favor the achievement
of complete clinical remission in juvenile dermatomyositis. Certain complications cannot be
avoided, and thus more effective treatments and monitoring strategies are needed for better
control of juvenile dermatomyositis.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Juvenile dermatomyositis (JDM) is a rare idiopathic chronic
disease that accounts for 85% of idiopathic inflammatory
myopathies in children.1 It is characterized by typical skin
rash and proximal muscle weakness, but it may further
affect other organs, including the heart, lungs, and
gastrointestinal tract. Long-term complications such as
joint contracture and muscle wasting may result in child-
hood disability. Fatal cases have also been reported,
especially when it affects the cardiopulmonary system. Its
pathogenesis remains unclear. Some evidence suggests that
JDM may be caused by environmental triggers, immune
dysfunction, and specific tissue responses (particularly
those of muscles, skin, and small vessel endothelium) in
genetically susceptible individuls.2
There is no standard treatment for JDM to date. Bitnum
et al3 reported that prior to the steroid era of 1960s, one-
third of affected children recovered completely, one-third
died, and those remaining had significant disability. How-
ever, clinical and functional prognosis has been improved
significantly after the introduction of corticosteroids,4
which remain the mainstay of treatment today, with or
without other immunosuppressive agents or intravenous
immunoglobulin (IVIG).
This study aimed to explore important prognostic factors
of JDM in children for predicting clinical outcomes of such
patients.
2. Materials and methods
2.1. Patients
This clinical epidemiologic study was approved by the
Institutional Review Board in advance. The medical charts
of JDM patients 18 years of age who were treated at the
Department of Pediatrics, National Taiwan University Hos-
pital, between June 1989 and December 2009 were
reviewed, which included patients’ clinical presentations,
initial laboratory data, complications, and clinical out-
comes. JDM was diagnosed based on the criteria of Bohan
and Peter published in 1975,5 which included typical skin
rash and two or more of the following symptoms and signs:
(1) symmetric proximal muscle weakness; (2) biopsy-proven
myositis; (3) elevated serum muscle enzyme levels; and (4)
electromyographic changes of myositis. Muscle weakness
was described mostly as difficulty in climbing stairs or
getting up from squatting position, and less frequently as
difficulty in combing hair or getting dressed by patientsthemselves. Patients with typical skin rash without evi-
dence of muscle weakness or inflammation were defined as
amyopathic dermatomyositis (DM). Patients who had evi-
dence of mixed connective tissue disease, systemic lupus
erythematosus (SLE), scleroderma, or overlapping connec-
tive tissue syndromes were excluded from this study.
2.2. Data
The demographic and clinical parameters were recorded,
which included the following: sex, onset age, initial symp-
toms and signs, duration of untreated disease, initial lab-
oratory data, reports of electromyography and muscle
biopsy, concurrent medications, duration of corticosteroid
treatment, occurrence of flares, complications during
treatment, and the final disease status during the follow-up
period. The date of disease onset was defined as the
earliest date the patient reported symptoms that were
consistent with JDM. The duration of untreated disease was
the time period from disease onset to the start of medical
treatment. According to the definitions of the International
Myositis Assessment and Clinical Studies Group,6 complete
clinical response was defined as no evidence of active
myositis for 6 months while receiving medications, and
complete clinical remission was defined as no evidence of
active myositis for 6 months without receiving any med-
ications. Absence of active myositis was defined as normal
muscle strength and normal muscle enzyme levels during
follow-up. Patients with clinical or laboratory evidence of
increasing skin or muscular symptoms requiring adjustment
of medications during follow-up were considered to expe-
rience juvenile DM flare.
2.3. Statistical analysis
Statistical analysis was performed using the R 3.0.2 soft-
ware (R Foundation for Statistical Computing, Vienna,
Austria). In statistical testing, a two-sided p value of 0.1
was considered statistically significant due to the relatively
small sample size. Distributional properties of continuous
variables were expressed as mean  standard deviation
(SD) and range, categorical variables were presented in
terms of frequency and percentage, and the survival curve
of time to complete clinical remission was plotted using the
KaplaneMeier estimates. In univariate analysis, Wilcoxon
rank-sum test, Chi-square test, and Fisher’s exact test were
used to examine the differences in the distributions of
continuous and categorical variables between patients with
and without complete clinical remission. Similarly, log-rank
test was used to examine the effects of continuous
Table 1 Demographics, clinical features, and initial lab-
oratory data at disease onset in 39 patients with juvenile
dermatomyositis.
Variable Mean  SD (range) or
frequency (%)
Male 13 (33.3)
Age at disease onset (mo) 81.97  46.63 (25e216)
Age at diagnosis (mo) 87.97  45.90 (28e213)
Duration of untreated
disease (mo)
6.08  6.59 (0e24)
Symptoms at disease onset
Malar rash 22 (56.4)
Gottron’s papule 32 (82.1)
Heliotroph sign 29 (74.4)
Skin ulcer 1 (2.6)
Vasculitis 1 (2.6)
Muscle weakness 32 (82.1)
Gowers’ sign 23 (59.0)
Myalgia 7 (18.0)
Arthralgia 7 (18.0)
Arthritis 5 (12.8)
GI symptoms 3 (7.7)
Swallowing difficulty 4 (10.3)
Calcinosis 1 (2.6)
Oral ulcer 1 (2.6)
Photosensitivity 3 (7.7)
Clinical review of juvenile dermatomyositis 33variables or categorical variables on time to complete
clinical remission. Next, multivariate analysis was con-
ducted by fitting Cox’s proportional hazards model to es-
timate the effects of prognostic factors simultaneously on
time to complete clinical remission. The goodness-of-fit
measures, including concordance and adjusted general-
ized R2, were examined to assess the goodness-of-fit of
fitted Cox’s proportional hazards models. The concordance
is equivalent to the estimated area under the receiver
operating characteristic curve, and thus concordance value
0.7 suggests an acceptable level of discrimination power.
The values of adjusted generalized R2 (0  R2  1) are
usually low for Cox’s proportional hazards modeldin our
experience, adjusted generalized R2  0.15 indicates an
acceptable fit for Cox’s proportional hazards model. If a
separation (or monotone likelihood) problem occurs, the
likelihood ratio test is used to replace Wald’s test for
computing the p value in Cox’s proportional hazards model.
The statistical tools of regression diagnostics for the veri-
fication of proportional hazards assumption, residual anal-
ysis, detection of influential cases, and check of
multicollinearity were applied to discover any model or
data problems. Finally, based on the well-fitted final Cox’s
proportional hazards model, covariate-adjusted survival
curves for time to complete clinical remission were drawn
in different scenarios for predicting complete clinical
remission.Muscle enzymes at disease onset
CK (U/L)* 1404.38  3202.98
(40.0e17669.0)
LDH (U/L)y 1040.86  684.89
(71.0e3000.0)
AST (U/L)z 126.22  167.04
(14.0e648.0)
AST Z aspartate aminotransferase; CK Z creatine kinase;
GI Z gastrointestinal; LDH Z lactate dehydrogenase;
SD Z standard deviation.
* One record was missing, CK normal range: 38e160 U/L.
y Four records were missing, LDH normal range: 230e460 U/L.
z Two records were missing, AST normal range: male <37 U/L,
female <31 U/L.3. Results
Demographics, clinical symptoms and signs, and initial
laboratory data at disease onset of the 39 patients with JDM
are summarized in Table 1. No one had a family history of
JDM. The ratio of females (n Z 26) to males (n Z 13) was
2:1, and the mean age at disease onset was 81.97  46.63
months. The most common initial presentations were Got-
tron’s papule (82.1%) and muscle weakness (82.1%).
Medications used by the patients were reviewed. The
most frequently used medications were oral corticosteroids
(92.3%), followed by azathioprine (85.6%), hydroxy-
chloroquine (76.95%), nonsteroidal anti-inflammatory drugs
(61.5%), cyclosporin A (56.4%), IVIG (41.0%), and etanercept
(10.3%). In this study, 16 (41%) patients received IVIG
therapy monthly for a total of nine courses on average
within a mean follow-up period of 79 months. Indications
for IVIG therapy included disease exacerbation, inability to
reduce the dose of steroid, replacement of cytotoxic agents
because of complications, and severe initial manifesta-
tions. Most patients showed improved muscular condition
after the first three courses of IVIG. Other therapies such as
methylprednisolone pulse therapy, methotrexate, cyclo-
phosphamide, and sulfasalazine were also used concur-
rently for disease control.
Among 39 patients, seven with typical skin rashes but
without clinical muscle weakness were classified as pa-
tients with amyopathic DM. The mean muscle enzyme
levels were almost nine times higher in patients with
muscle weakness than in those without muscle weakness,
although some patients in the former group had normal
levels. No statistical difference was found between these
two groups in terms of mean age at disease onset,concurrent therapy, duration of oral prednisolone treat-
ment, need for IVIG treatment, and incidence of calcinosis
during the follow-up period. Nevertheless, four (12.9%)
patients with muscle weakness had disability that required
rehabilitation or surgical intervention, but no patient in the
amyopathic DM group ended up with disability.
After excluding one with an incomplete record, the
remaining 31 patients with muscle weakness were further
analyzed. Twenty-two (70.97%) achieved complete clinical
response. According to the KaplaneMeier estimate of sur-
vival curve for time to complete clinical response (not
shown in figures), the estimated median time to complete
clinical response decreased at 18 months. However, after
complete clinical response was achieved, 16 (72.7%) had at
least one disease flare (range: 1e8 times) during follow-up.
There was no statistical difference in age of disease onset,
sex, mean duration to achieve complete clinical response,
and medical treatments between the patients achieving
34 C. Sun et alcomplete clinical response (n Z 22) with (n Z 16) and
without (n Z 6) disease flares.
As listed in Table 2, among the 31 patients with muscle
weakness, six (19.4%) finally achieved complete clinical
remission and 25 (80.6%) did not. Univariate analysis found
that female (p Z 0.0712) patients, patients without Gow-
ers’ sign (p Z 0.0101), or patients with photosensitivity
(p Z 0.0323) had higher probabilities to achieve complete
clinical remission, among which sex and photosensitivity
completely separated the outcome (i.e., a 0 in one of the 4
cells). No patients who received antitumor necrosis factor
(anti-TNF) treatment achieved complete clinical remission.
Calcinosis was found in both groups. The KaplaneMeierTable 2 Comparison between 31 patients with and without com
Variable Remission (n Z 6)
Age at disease onset (mo) 93.00  41.67 (40
Sexy
Female 6 (28.6%)
Male 0 (0%)
Duration of untreated disease (mo) 9.17  8.80 (1e24
Symptoms present at disease onset
Gowers’ signz
No 3 (37.5%)
Yes 3 (13.0%)
Photosensitivityx
No 4 (13.8%)
Yes 2 (100%)
Initial laboratory data at disease onset
CPK (U/L) 1880.33  2312.46
LDH (U/L) 1374.60  1002.60
AST (U/L) 161.20  163.61 (
Amount of concurrent therapy 4.33  2.25 (2e8)
Duration of prednisolone treatment (mo) 81.00  69.78 (11
Patients received IVIG
No 5 (29.4%)
Yes 1 (7.1%)
Patients ever received anti-TNFa
No 6 (22.2%)
Yes 0 (0%)
Calcinosis during follow-up
No 3 (15.8%)
Yes 3 (25.0%)
* Eight patients were excluded from this analysis, among whom sev
Sample statistics presented in this table are mean  SD and range for
variables. The listed p values of statistical tests were calculated using
exact test for categorical variables.
y Univariate analysis of complete clinical remission (yes vs. no) yielde
complete clinical remission yielded the following: (1) the likelihood ra
Wald test: c Z 0, degrees of freedom Z 1, p Z 0.9992 > 0.1; and (
p Z 0.1649 > 0.1.
z Univariate analysis of complete clinical remission (yes vs. no) yielde
complete clinical remission yielded the following: (1) the likelihood ra
Wald test: cZ 4.82, degrees of freedomZ 1, pZ 0.0282 < 0.1; and
p Z 0.0101 < 0.1.
x Univariate analysis of complete clinical remission (yes vs. no) yielde
complete clinical remission yielded the following: (1) the likelihood r
Wald test: c Z 0, degrees of freedom Z 1, p Z 0.9600 > 0.1; and
p Z 0.9600 > 0.1.
ASTZ aspartate aminotransferase; CPKZ creatine phosphokinase; IV
SD Z standard deviation; TNFa Z tumor necrosis factor a.estimate of survival curve in Figure 1A showed that the
estimated median time to complete clinical remission was
about 101 months.
Multivariate analysis was conducted by fitting Cox’s
proportional hazards model to identify important pre-
dictors of time to complete clinical remission. As shown
in Table 3, female sex, negative Gowers’ sign at disease
onset, and positive photosensitivity at disease onset were
favorable factors to achieve complete clinical remission.
Moreover, based on the fitted final Cox’s proportional haz-
ards model (Table 3), covariate-adjusted survival curves
were drawn in Figure 1B and C for making predictions for
complete clinical remission.plete clinical remission.*
No remission (n Z 25) p
e144) 85.12  50.35 (25e216) 0.5995
0.0712
15 (71.4%)
10 (100%)
) 5.40  6.65 (0e24) 0.2062
0.0101
5 (62.5%)
20 (87.0%)
0.0323
25 (86.2%)
0 (0%)
(62e6000) 1571.48  3788.14 (47e17,669) 0.4383
(71e2449) 1076.57  682.17 (344e3000) 0.6001
19e412) 146.40  184.25 (14e648) 0.9556
5.52  1.98 (3e10) 0.1790
e207) 33.16  35.36 (1e138) 0.0511
0.1848
12 (70.6%)
13 (92.9%)
0.5614
21 (77.8%)
4 (100%)
0.6526
16 (84.2%)
9 (75.0%)
en were of amyopathic type and one had an incomplete record.
continuous variables, and frequency (percentage) for categorical
the Wilcoxon rank-sum test for continuous variables and Fisher’s
d Fisher’s test: pZ 0.1411. Univariate survival analysis of time to
tio test: cZ 3.25, degrees of freedomZ 1, pZ 0.0712 < 0.1; (2)
3) the score (log-rank) test: c Z 1.93, degrees of freedom Z 1,
d Fisher’s test: pZ 0.1605. Univariate survival analysis of time to
tio test: cZ 4.71, degrees of freedomZ 1, pZ 0.0300 < 0.1; (2)
(3) the score (log-rank) test: cZ 6.62, degrees of freedomZ 1,
d Fisher’s test: pZ 0.0323. Univariate survival analysis of time to
atio test: c Z 0, degrees of freedom Z 1, p Z 0.9598 > 0.1; (2)
(3) the score (log-rank) test: c Z 0, degrees of freedom Z 1,
IGZ intravenous immunoglobulin; LDHZ lactate dehydrogenase;
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the 39 patients assessed at the end of follow-up are re-
ported in Table 4. Only 13 (33.33%) patients were symptom
free at the end of follow-up, whereas the remaining 26
suffered from different complications. None of them
developed malignancy, but two (5.13%) died during the
follow-up period.4. Discussion
JDM is a rare, often chronic, autoimmune disease of
childhood. Clinical features are associated with systemic
vasculopathy and are central to the diagnosis. Demographic
statistics in the current study are similar to those of a
previous study conducted in America, in which the mean
age of disease onset was 7.54 years, mean duration of un-
treated disease 0.07e98 months (median, 4.04 months),
and female-to-male ratio about 1.9:1.7 Compared with the
domestic data in Taiwan, the female-to-male ratio in our
study is slightly lower; however, most frequently found
cutaneous features at disease onset such as Gottron’s
papule, malar rash, and heliotroph sign are similar.
In the current study, seven patients (17.9%) had cuta-
neous manifestations but without muscle weakness. Three
had elevated muscle enzymes and were considered to have
hypomyopathic DM,8 whereas the other four were classified
as patients with amyopathic DM. In the literature, amyo-
pathic DM accounts for 5e10% of all cases of DM, with a
higher prevalence among Asians.9e11 Most amyopathic DM
cases do not progress to clinically evident myositis, espe-
cially among juvenile-onset patients. In three case series of
patients with amyopathic DM who received no systemic
therapy, two of 28 adults (7%) and none of the 20 juvenile
patients progressed to symptomatic muscle disease in a
mean follow-up period of 5 years.11e13
Predictive factors for the progression of amyopathic DM to
classical DM have not been identified clearly. Calcinosis, skin
ulcerations, andmuscleweaknessmay develop several years
later during follow-up, since aggressive treatment is sug-
gested by some clinicians.14,15 However, some cases have
been reported to have true amyopathic DM that resolved
spontaneously.16,17 Thus, there is still considerable contro-
versy about the treatment strategy for amyopathic DM.
In the current study, seven patients remained clinically
without muscle weakness after a mean follow-up of 10
years. However, most still required systemic prednisolone
treatment for an average of 32 months, which was similar
to those with muscle weakness (mean, 39.81 months).
Three patients (42.86%) without muscle weakness eventu-
ally developed calcinosis even under prednisolone treat-
ment. The prognosis of amyopathic DM, unlike in adult
groups with increasing risks for interstitial lung disease and
malignancy,18,19 is generally excellent among pediatric
patients.
It is well recognized that a proportion of patients with
muscle weakness has normal muscle enzyme levels at the
time of diagnosis.20 Furthermore, levels of creatine kinase
and other muscle enzymes (i.e., aspartate aminotrans-
ferase and lactate dehydrogenase) do not correlate well
with the improvement of muscle strength.21 It is suggested
that the inconsistency between laboratory data and clinicalpresentation is partially due to the fact that muscle en-
zymes often improve weeks before improvement in muscle
strength, while the rise is more than 1 month prior to
clinical relapse.22 This finding is consistent with that of the
current study, making it difficult to monitor the disease. To
better determine occult disease activity, a number of
immunological biomarkers, including interferon a, down-
stream targets of interferon a, or interleukin-17 and
interferon-regulated genes, appear to be promising. These
are now under investigation and may be proved to be sen-
sitive markers of disease activity.2,23
Since the 1970s, the standard treatment of JDM has been
administration of high-dose oral corticosteroid daily, which
is continued until clinical and laboratory improvements are
evident, and then slowly reduced over at least a 2-year
period.24 However, most patients experience side effects
from corticosteroid treatment, including avascular hip
joints necrosis, osteoporosis, and retarded growth velocity.
Steroid-sparing therapies have been introduced to reduce
the cumulative doses of corticosteroid use. Previous studies
suggest that children who receive methotrexate at disease
onset have half of the cumulative corticosteroid dose, less
weight gain, and improved height velocity, while achieving
the same disease control as those who are treated with
corticosteroid only.25
IVIG was efficacious in a controlled trial for adult DM.26
Several case series have shown the effectiveness of IVIG
for treating JDM.27e29 The proposed mechanism for the
beneficial effect is intercepting the assembly and deposi-
tion of C5beC9 membranolytic attack complex on the
endomysial capillaries through the formation of complexes
between the infused immunoglobulin and C3b, thereby
preventing the incorporation of activated C3 molecules into
C5 convertase.28,30
TNFa has recently been recognized as an important
cytokine in the pathogenesis of DM.2,31 Moreover, the TNFa-
308A allele has been associated with a disease course that
is more resistant to the immunosuppressive therapy and
may be complicated by a higher frequency of pathologic
calcification.32 The use of anti-TNF agents (e.g., eta-
nercept or infliximab) in children has only been reported in
a few meeting abstracts. Reports of their effectiveness in
adult myositis are conflicting.33,34
In the current study, four patients received anti-TNF
agents (etanercept), of whim two achieved complete clin-
ical response after 15 and 18 months of treatment
(including etanercept and corticosteroid), but one had
disease flares later during follow-up and required cortico-
steroid control. The other two patients did not improve
well and were still under multiple medications. One was
bedridden and the other had a refractory disease course.
None achieved complete clinical remission. Treatment with
an anti-TNF agent may be effective for adults with re-
fractory DM or polymyositis, but it was not that promising in
the current study.
Complete clinical remission is an important endpoint.
We found that female sex and photosensitivity at disease
onset are positive factors for complete clinical remission,
whereas male sex and the presence of Gowers’ sign at
disease onset are adverse factors.
Among 13 male patients in the current study, none
achieved complete clinical remission during the follow-up
36 C. Sun et al
Table 3 Multivariate analysis of the predictors of time to complete clinical remission using Cox’s proportional hazards model
in 31 patients.*
Covariatey Regression
coefficient
Standard error z value pz Hazard ratio 95% confidence
interval
Male versus female 19.7825 21,936.2229 0.0009 0.2763 2.5620  109 0e9999þ
Gowers’ sign (yes vs. no) 1.8189 1.1589 1.5696 0.0849 0.1622 0.0167e1.5721
Photosensitivity (yes vs. no) 0.4797 1.4227 0.3372 0.7371 1.6156 0.0994e26.2651
* All covariates satisfied the proportional hazards assumption. All variance inflating factors were <1.5. Adjusted generalized
R2 Z 0.376 > 0.15 and concordance Z 0.825 > 0.7 indicated a good fit.
y The overall likelihood ratio test: cZ 6.44, degrees of freedomZ 3, pZ 0.0920 < 0.1. The overall score (log-rank) test: cZ 7.18,
degrees of freedom Z 3, p Z 0.0663 < 0.1.
z To accommodate the separation (monotone likelihood) problem (see Table 2), the partial likelihood ratio test was used to compute
the p value.
Table 4 Clinical outcomes and major complications of 39
patients with juvenile dermatomyositis at the end of follow-
up.
Clinical outcomes Frequency (%)
Symptom free 13 (33.33)
Mild atrophy or contracture 11 (28.21)
Disability* 4 (10.26)
Calcinosis 15 (38.46)
GI perforation 1 (2.56)
Avascular necrosis of the hip joint 1 (2.56)
Pulmonary involvementy 4 (10.26)
Deathz 2 (5.13)
GI Z gastrointestinal.
* Patients required rehabilitation or auxiliary supports.
y Patients had interstitial pneumonitis or restricted lungs (3
proven by lung biopsy, 1 by clinical diagnosis).
z One patient died of interstitial pneumonitis with respiratory
failure and septic shock at the age of 5, and the other died of
end-stage renal failure and intracranial hemorrhage with her-
niation at the age of 29.
Clinical review of juvenile dermatomyositis 37period. It is assumed that females are more susceptible to
autoimmune diseases than males. In SLE, for example,
various reasons have been proposed for this sex discrep-
ancy, including sex hormone hypothesis, sex chromosome
hypothesis, and intrauterine selection hypothesis.35 How-
ever, previous studies also suggest that, although less
common in men, SLE tends to run a more severe course
when it occurs.36 The reason why men with SLE tend to
have worse outcomes has yet to be determined. Whether
men with JDM have similar pathogenic patterns to men with
SLE warrants further investigations.Figure 1 (A) KaplaneMeier estimate (solid line) and 95% confiden
clinical remission (nZ 31). As shown in the figure, the estimated m
period was about 101 months. (B) Estimated covariate-adjusted surv
fitted final Cox’s proportional hazards model (n Z 31), which rep
patients without Gowers’ sign and with positive photosensitivity at
clinical remission. (C) Estimated covariate-adjusted survival curve f
Cox’s proportional hazards model (n Z 31), which depicts the wo
Gowers’ sign and without positive photosensitivity at the onset
remission. All male patients failed to achieve complete clinical remAnother adverse factor for complete clinical remission is
the presence of Gowers’ sign. Gowers’ sign generally sug-
gests more severe muscular involvement, which may be
more difficult to control and require longer treatment.
However, photosensitivity was found to be a favorable
factor for complete clinical remission in this study. It is
believed that ultraviolet light-induced apoptotic cell in skin
leads to a suprathreshold concentration of antigenic pep-
tides. Apoptotic cells are normally cleared through nonin-
flammatory pathways. In the presence of genetic
polymorphisms that lead to over- or underexpression of
proteins involved in promoting apoptosis (e.g., TNF pro-
moter polymorphism) or impairing clearance (e.g.,
decreased serum mannose binding lectin), increased
apoptotic cells may lead to cutaneous autoimmune condi-
tions found in patients with SLE or JDM.37
Although photosensitivity is not easily reported among
pediatric patients because it may be underestimated,
several studies have shown that recurrent photosensitive
dermatitis can be an early sign of occult JDM38,39 that re-
quires further attention. Speculations about the finding in
this series may be that photosensitivity at disease onset
may lead to an early intervention and result in better dis-
ease control. The patients may also be more sensitive to
medications in some ways. However, reasons for this finding
remain unclear, and more clinical experiences from other
series should be investigated.
It took 18 months for half of the patients with muscle
weakness to achieve complete clinical response. However,
72.7% experienced at least one disease flare during follow-
up. It took 8.5 years for half of the patients to achieve
complete clinical remission without disease flares. These
findings suggest that JDM runs a chronic and heterogenic
course that requires a long-term follow-up, even ifce interval (dashed line) of survival curve for time to complete
edian time to complete clinical remission during the follow-up
ival curve for time to complete clinical remission, based on the
resents the best scenario: as shown by the solid line, female
the onset of the disease were most likely to achieve complete
or time to complete clinical remission, based on the fitted final
rst scenario: as shown by the solid line, female patients with
of the disease were least likely to achieve complete clinical
ission by the end of follow-up.
38 C. Sun et alcomplete clinical response is achieved. The mortality rate
in this study is slightly higher than other series (5.13% vs.
4.2% in a Brazilian series40) but similar to domestic data in
Taiwan. However, one-third of patients were symptom free
after treatment at the end of follow-up.
In conclusion, JDM is a chronic and heterogenic inflam-
matory myopathy that requires corticosteroids and other
immunosuppressive agents for disease control. The time
required to achieve complete clinical remission is relatively
long, but female sex and the presence of photosensitivity at
disease onset may be favorable factors to achieve this
endpoint. Male sex and positive Gowers’ sign at disease
onset are adverse factors for disease remission that may
require more attention and aggressive treatment. Exact
reasons for these findings require further investigations.
Although one-third of patients in this series reached the
symptom-free status after treatment, certain complica-
tions cannot be avoided, highlighting the need for more
efficient treatment strategies and monitoring parameters
for better disease control.
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